Table 3 Cytokines, inflammatory markers, and clinical parameters in active-AS patients undergoing anti-TNF therapy vs. healthy controls
From: IL-23/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patients
Active-AS patients | Healthy controls (n = 47) | |||||
|---|---|---|---|---|---|---|
Variable | Baseline (n = 47) | 12 months (n = 47) | 24 months (n = 47) | p valuea | p valueb | |
ESR (mm/hour) | 29.70 ± 23.32 | 9.59 ± 12.10 | 10.53 ± 13.90 | <0.001 | NA | |
CRP (mg/l) | 29.71 ± 39.56 | 7.57 ± 13.50 | 5.13 ± 6.23 | <0.001 | NA | |
mSASSS | 15.83 ± 18.73 | NA | 19.49 ± 19.61 | <0.001 | NA | |
ASDAS-CRP | 3.93 ± 1.04 | 2.08 ± 1.12 | 1.93 ± 1.11 | <0.001 | NA | |
BASFI | 5.80 ± 2.33 | 3.60 ± 2.97 | 3.18 ± 2.95 | <0.001 | NA | |
BASMI | 4.53 ± 2.70 | 3.70 ± 2.72 | 3.34 ± 2.56 | <0.001 | NA | |
ASQoL | 12.59 ± 4.83 | 6.57 ± 5.51 | 5.83 ± 5.81 | <0.001 | NA | |
NSAID intake (0–100) | 70.26 ± 44.78 | 62.43 ± 47.56 | 45.16 ± 46.37 | <0.01 | NA | |
IL-17A (pg/ml) | 1.62 (1.06–2.98) | 1.58 (1.14–3.52) | 1.69 (0.78–3.46) | 0.78 | 1.57 (1.04–2.17) | 0.96 |
IL-22 (ng/ml) | 0.00 (0.00–0.00) | 0.00 (0.00–0.00) | 0.00 (0.00–0.00) | 0.87 | 0.00 (0.00–0.00) | 0.59 |
IL-23 (ng/ml) | 0.08 (0.04–0.17) | 0.04 (0.02–0.17) | 0.06 (0.03–0.15) | 0.38 | 0.02 (0.00–0.05) | <0.001 |
PGE2 (pg/ml) | 19.46 (5.41–102.58) | 23.73 (4.72–102.82) | 35.50 (5.88–75.82) | 0.98 | 7.66 (3.30–30.32) | 0.03 |